Whittier Trust Co. of Nevada Inc. Has $7.86 Million Stake in Amgen Inc. $AMGN

Posted by Brian Himes on Jul 6th, 2026

Whittier Trust Co. of Nevada Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 22,943 shares of the medical research company’s stock after purchasing an additional 1,396 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Amgen were worth $7,860,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. grew its stake in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after buying an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC purchased a new stake in shares of Amgen during the fourth quarter worth $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after acquiring an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Amgen in the fourth quarter worth $22,441,000. Finally, Robinhood Asset Management LLC purchased a new position in shares of Amgen in the fourth quarter valued at $17,526,000. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $374.15 on Monday. The firm has a market capitalization of $201.93 billion, a price-to-earnings ratio of 26.04, a P/E/G ratio of 3.68 and a beta of 0.41. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The stock has a fifty day moving average of $342.43 and a 200 day moving average of $348.09. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the company earned $4.90 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.39 EPS for the current fiscal year.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research note on Wednesday, April 8th. Jefferies Financial Group assumed coverage on Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price for the company. Mizuho upped their price target on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. UBS Group increased their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $400.00 price objective on shares of Amgen in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $355.50.

View Our Latest Analysis on Amgen

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.